SCHEMBL318699

SCHEMBL318699

O=C(CCCCCBr)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
MAPK1 P28482 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
TDP1 Q9NUW8 2/20 0.53
KMT2A Q03164 2/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A3 Q01959 1/20 0.53
EPHX2 P34913 1/20 0.51
LMNA P02545 2/20 0.49
HTT P42858 1/20 0.46
FAAH O00519 1/20 0.45
MGLL Q99685 1/20 0.45
HCAR2 Q8TDS4 1/20 0.45
NOTUM Q6P988 1/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365835 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL18762322 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL3871093 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL1365591 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL24677830 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL1419528 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL24678064 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL7545592 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL5386843 1.00 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1TDP1KMT2A
SCHEMBL1363586 0.98 ALDH1A1 (0.59) ALDH1A1MAPK1L3MBTL1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605461-B2 Hydrogel compositions and uses thereof Shoichet, Molly Sandra (CA) 2026-04-21 US disclosed
EP-4584241-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2025-07-16 EP disclosed
CN-119836414-A Lipids for lipid nanoparticle formulations 爱康泰生治疗公司 2025-04-15 CN disclosed
US-20240270679-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS ACUITAS THERAPEUTICS INC (CA) 2024-08-15 US disclosed
US-20240092819-A1 NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR SANOFI SA (FR) 2024-03-21 US disclosed
CN-114466869-B Hydrogel composition and use thereof 莫莉·桑德拉·萧伊凯特 2024-03-19 CN disclosed
WO-2024054843-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2024-03-14 WO disclosed
US-20230286902-A1 LIPID NANOPARTICLE COMPOSITION Suzhou Abogen Biosciences Co., Ltd. (CN) 2023-09-14 US disclosed
EP-4232455-A2 NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR Sanofi (FR) 2023-08-30 EP disclosed
CN-116368146-A Novel ligands for asialoglycoprotein receptors 赛诺菲 2023-06-30 CN disclosed
WO-1994008945-A1 SUBSTITUTED ETHANOLAMINE ESTERS BYK NEDERLAND BV (NL) 1994-04-28 WO disclosed
US-5053503-A For joining antibodies and metallic radionuclides CENTOCOR (US) 1991-10-01 US disclosed
WO-1991008191-A1 NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHOD OF USE THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1991-06-13 WO disclosed
US-5010176-A Malonate linker ELI LILLY AND COMPANY (US) 1991-04-23 US disclosed
WO-1991000257-A1 NOVEL POTENT INDUCERS OF TERMINAL DIFFERENTIATION AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1991-01-10 WO disclosed
CN-1042546-A ANTIBODY-DRUG CONJUGATES LILLY CO ELI (US) 1990-05-30 CN disclosed
EP-0368668-A2 Antibody-drug conjugates ELI LILLY AND COMPANY (US) 1990-05-16 EP disclosed
EP-0094080-B1 PYRIDO(2,1-B)QUINAZOLINE DERIVATIVES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1987-09-09 EP disclosed
US-4551460-A ANTICOAGULANTS, CARDIOVASCULAR DISORDERS HOFFMANN-LA ROCHE INC. (US) 1985-11-05 US disclosed
EP-0094080-A2 Pyrido(2,1-b)quinazoline derivatives F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1983-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286902-A1 LIPID NANOPARTICLE COMPOSITION CETP, NPC1, LCAT ALDH1A1 4587/4885MAPK1 3444/4885L3MBTL1 1165/4885
US-20240270679-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS LIPA, LIPC, LDLR ALDH1A1 1036/4885MAPK1 2288/4885L3MBTL1 99/4885
US-12605461-B2 Hydrogel compositions and uses thereof CD44, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1 ALDH1A1 47/4885MAPK1 2198/4885L3MBTL1 1213/4885
US-20240092819-A1 NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR ASGR1, HAVCR2, SIGLEC7 ALDH1A1 2427/4885MAPK1 3690/4885L3MBTL1 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.